News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PerkinElmer, Inc. (PKI) and BioLegend Announce Custom Immunoassay Development Collaboration for Drug Discovery Research


5/12/2009 7:29:38 AM

Bookmark and Share

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced an assay development and sample testing collaboration with BioLegend, Inc., a San Diego company focused on providing quality immunological reagents to biomedical research communities.

Under this agreement, BioLegend is now able to offer immunoassay development and bioanalytical testing based on PerkinElmer’s “No Wash” homogenous bead-based AlphaLISA® assay technology. AlphaLISA comprises highly sensitive and quantitative assays with broader dynamic ranges than standard ELISAs, saving time in laboratory workflows, and eliminating labor intensive wash steps that are difficult to automate.

These assay development and testing services integrate BioLegend’s strong position in high quality antibody production and assay development capabilities with PerkinElmer's unique technology and instrumentation. The collaboration provides scientists with broader access to the AlphaLISA technology and offers assays with extremely high detection sensitivities, currently very difficult to achieve with many existing ELISA assays. Furthermore, the advantages of AlphaLISA technology allow for easy integration into automated high throughput testing systems, including the JANUS® liquid handling system from PerkinElmer.

"The future of high throughput assays lies in an increased need for automation. Many current immunological assay platforms have major drawbacks when it comes to meeting requirements for automation in the lab," said Brad Kraft, president of BioLegend. “We feel this collaboration with PerkinElmer is therefore a timely and highly promising advance that gives researchers greater understanding of basic disease biology and pathobiology, particularly when applied to biomarker assays."

Richard M. Eglen, PhD, president, Bio-discovery, PerkinElmer, said, "PerkinElmer is committed to extending the benefits of our proprietary AlphaLISA platform to researchers globally, across pharma, biotech and academic laboratories. Combining PerkinElmer’s technologies with BioLegend’s unique immunoassay development capabilities enables scientists to benefit from reduced barriers to discovery such as time or resource constraints.”

About BioLegend, Inc.

BioLegend develops and manufactures world-class, cutting-edge antibodies, reagents, immunoassay products and services for biomedical research, offered at an outstanding value. Its product areas include cell immunophenotyping, cytokines and chemokines, adhesion molecules, cancer biomarker research, T regulatory cells, stem cells, innate immunity, cell-cycle analysis, apoptosis, and modification-specific antibodies. All of BioLegend’s reagents and kits are supported by superior customer service and come with a quality guarantee. BioLegend’s aggressive product development program, through technology licensing, collaborations, and internal hybridoma development, produces strategic reagents for use in a variety of applications including flow cytometry, ELISA, multiplex immunoassays, immunoprecipitation, Western blotting, immunofluorescence microscopy, immunohistochemistry, and in vitro or in vivo functional assays.

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2 billion in 2008, has around 8,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Contact:

For PerkinElmer: Mario Fante, 781 663 5602 mario.fante@perkinelmer.com or For BioLegend: Dzung Nguyen, 858 455-9588 dnguyen@biolegend.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES